Insmed: Wells Fargo Reiterates Overweight, Raises PT to $140 from $130

Insmed: Wells Fargo Reiterates Overweight, Raises PT to $140 from $130

Wells Fargo & Company has reiterated its "Overweight" rating on Insmed Inc. (NASDAQ: INSM), raising its price target to $140 from $130. The updated recommendation comes amid positive analyst sentiment for the biopharmaceutical company.

Wells Fargo's analysts, led by Tiago Fauth, believe that Insmed's pipeline, particularly its focus on rare diseases, presents strong growth opportunities. The updated price target reflects the analysts' confidence in the company's ability to deliver on its growth prospects.

The latest update follows a series of positive analyst ratings and price target revisions for Insmed. In the past 90 days, 16 Wall Street analysts have issued "buy" ratings for the stock, with the average twelve-month stock price forecast standing at $112.71. The highest price target for INSM is $133.00, while the lowest is $96.00 [1].

Insmed's stock has seen a predicted downside of -3.89% based on analysts' 12-month stock forecasts. The consensus among Wall Street equities research analysts is that investors should "buy" INSM shares. The company has been rated by analysts at various institutions, including Bank of America, Citigroup, HC Wainwright, Jefferies Financial Group, JPMorgan Chase & Co., Leerink Partners, Mizuho, Morgan Stanley, Royal Bank Of Canada, The Goldman Sachs Group, UBS Group, and Wells Fargo & Company in the past 90 days [1].

Analysts like Insmed more than other "medical" companies. The consensus rating for Insmed is "Buy," while the average consensus rating for "medical" companies is "Moderate Buy." This page (NASDAQ:INSM) was last updated on 8/12/2025 by MarketBeat.com Staff [1].

References:
[1] https://www.marketbeat.com/stocks/NASDAQ/INSM/forecast/